BusinessOcera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic EncephalopathyBy Nasdaq OMXSep 19, 2016, 1:05 PM UTC
BusinessOcera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of HepatologyBy Nasdaq OMXApr 11, 2016, 1:05 PM UTC
BusinessOcera to Present at the 15th Annual Needham Healthcare ConferenceBy Nasdaq OMXApr 5, 2016, 8:25 PM UTC
BusinessOcera Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate UpdateBy Nasdaq OMXMar 3, 2016, 2:05 PM UTC
